Barok, Márk <br/><br/>
Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.  [electronic resource] 

 -  Cancer letters  Feb 2008 
 - 198-208 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0304-3835 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2007.10.043  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Agents--pharmacology<br/>Bone Marrow--drug effects<br/>Breast Neoplasms--blood<br/>Cell Line, Tumor<br/>Chromosomes, Human, X<br/>Drug Resistance, Neoplasm<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Histocompatibility Antigens Class I--analysis<br/>Humans<br/>Immunohistochemistry<br/>In Situ Hybridization, Fluorescence<br/>Leukocyte Common Antigens--analysis<br/>Mice<br/>Mice, SCID<br/>Neoplasm Metastasis<br/>Neoplastic Cells, Circulating--drug effects<br/>Rituximab<br/>Time Factors<br/>Trastuzumab<br/>Xenograft Model Antitumor Assays